MPN disease progression, or MPN progression, is the transformation over time of a myeloproliferative neoplasm (MPN) into a more aggressive form of the current disease, another MPN (PV, ET, MF), or, more rarely, to secondary acute myeloid leukemia (sAML) — which can lead to increased complications, disease symptoms, and generally poorer overall prognosis.

As a result, progression and its causes are a major concern for MPN patients, and a priority area of focus for researchers.

The word “progression” can feel intimidating but understanding how progression happens is our best chance at discovering meaningful intervention. By focusing on progression, we hope to learn enough to:

• Detect it early: Recognize changes in symptoms, labs, or genetic markers.

• Improve treatments: Help doctors intervene sooner and more effectively.

• Empower patients: Knowledge can make MPN progression feel less intimidating and allows patients to take more control of their care.

By reframing progression as an opportunity for action, the MPN PROGRESSion Registry can inspire the focused effort to uncover better treatments and result in more informed care decisions.

The MPN PROGRESSion Registry strives to revolutionize MPN research by:

• identifying the biomarkers for who will progress and why (e.g., by which mechanisms).

• supporting the development of new therapies aimed at slowing or stopping progression.

• spotting early signs of progression through detailed analysis of blood tests, symptoms, and genetic data, offering researchers a more nuanced understanding of disease progression.

• uncovering real-world challenges like care disparities and comorbidities.

• utilizing robust patient data to enable personalized treatment plans.

• identifying long-term patterns and trends that often only emerge from research that can be conducted over many years.